Blood Safety Online
Your Resource Center for Continuing Education and Training

About Cerus Corporation

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood.

The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cells system is in clinical development.

Our Core Values

  • The patient is our ultimate concern. We intend to make INTERCEPT for Platelets and Plasma the standard of care for blood safety globally.
  • We will be a dependable partner for all blood services to allow them to achieve their important mission, concentrating on ensuring the quality, supply, and operational efficiency of our products. No other company will know blood center operations better, nor provide better service.
  • We operate as one team and resolve to attract and retain the best people in the business. We operate in multiple cultures and geographies and work in a coordinated, mutually supportive fashion.
  • Integrity, perseverance, scientific rigor, and urgency are core to who we are.

For more information visit: www.cerus.com